Evidence map›Paper›PMID 39937083›Full record

ArticlePediatric blood & cancer2025

Vincristine Sulfate Liposome Injection With Combination Chemotherapy for Children, Adolescents, and Young Adults With Relapsed Acute Lymphoblastic Leukemia: A Therapeutic Advances in Childhood Leukemia and Lymphoma Consortium Trial.

Nirali N Shah, Eric S Schafer, Yueh-Yun Chi, Jemily Malvar, Kenneth M Heym, Andrew E Place, Melissa Burns, Bill H Chang, Tamra Slone, Anupam Verma and 17 more

Registry-linked trialAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric blood & cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02879643 (A Pilot Study of Vincristine Sulfate Liposome Injection), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02879643 phase1completednot on this map

A Pilot Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapse of Acute Lymphoblastic Leukemia

TypeinterventionalSponsorTherapeutic Advances in Childhood Leukemia ConsortiumRan2017 to 2024Enrolled29ConditionsALL, Childhood, Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia, AcuteArmsMarqibo
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. The logarithmic phase as a therapeutic direction: evaluating pharmacological strategies against cancer progression.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Nirali N ShahPediatric Oncology Branch, National Cancer Institute/Center for Cancer Research, National Institutes of Health, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0002-8474-9080
Eric S SchaferDivision of Hematology/Oncology, Department of Pediatrics, Baylor College of Medicine and Texas Children's Cancer and Hematology Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-7063-512X
Yueh-Yun ChiDivision of Hematology-Oncology, Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Jemily MalvarDivision of Hematology-Oncology, Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, California, USA.
Kenneth M HeymHematology and Oncology, Cook Children's Medical Center, Fort Worth, Texas, USA.ORCID https://orcid.org/0000-0002-6635-435X
Andrew E PlaceDana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0002-9604-4213
Melissa BurnsDana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0002-0953-766X
Bill H ChangDivision of Hematology and Oncology, Department of Pediatrics, Oregon Health & Science University, Portland, Oregon, USA.
Tamra SloneChildren's Medical Center, UT Southwestern, Dallas, Texas, USA.
Anupam VermaPediatric Specialists of Virginia, Fairfax, Virginia, USA.ORCID https://orcid.org/0000-0001-6555-7924
Nathan GossaiCenter for Cancer and Blood Disorders, Children's Minnesota, Minneapolis, Minnesota, USA.ORCID https://orcid.org/0000-0003-1693-4898
Peter H ShawDivision of Hematology and Oncology, Department of Pediatrics, Children's Wisconsin, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.ORCID https://orcid.org/0000-0002-9525-3224
Michael J BurkeDivision of Hematology and Oncology, Department of Pediatrics, Children's Wisconsin, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.ORCID https://orcid.org/0000-0001-6626-2773
Michelle HermistonPediatric Hematology/Oncology, Department of Pediatrics, University of California San Francisco, San Francisco, California, USA.
Reuven J SchoreDivision of Pediatric Oncology, Children's National Hospital/George Washington University SMHS, Washington, District of Columbia, USA.ORCID https://orcid.org/0000-0002-1582-2168
Todd CooperSeattle Children's Cancer and Blood Disorders Center, University of Washington, Seattle, Washington, USA.ORCID https://orcid.org/0000-0002-1203-2371
Melinda PaulyDepartment of Pediatric Hematology Oncology, Emory University and Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0001-8906-5836
Teresa RushingDivision of Hematology-Oncology, Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Paul JarosinskiPediatric Oncology Branch, National Cancer Institute/Center for Cancer Research, National Institutes of Health, Bethesda, Maryland, USA.
Ellynore FlorendoDivision of Hematology-Oncology, Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, California, USA.
Bonnie YatesPediatric Oncology Branch, National Cancer Institute/Center for Cancer Research, National Institutes of Health, Bethesda, Maryland, USA.
Brigitte C WidemannPediatric Oncology Branch, National Cancer Institute/Center for Cancer Research, National Institutes of Health, Bethesda, Maryland, USA.
Cody J PeerClinical Pharmacology Laboratory, National Institutes of Health Clinical Center, Bethesda, Maryland, USA.
William D FiggClinical Pharmacology Laboratory, National Institutes of Health Clinical Center, Bethesda, Maryland, USA.
Lewis B SilvermanDivision of Pediatric Hematology, Oncology and Stem Cell Transplantation, Columbia University Medical Center, New York, New York, USA.
Deepa BhojwaniDivision of Hematology-Oncology, Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Alan S WayneDivision of Hematology-Oncology, Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.

Funding

Using Clinical Pharmacology Principles to Develop New Anticancer TherapiesZICSC006537 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI FIGG, WILLIAM DOUGLAS · 2009 to 2025
$14.4M
Immunotherapeutic approaches to treat pediatric hematologic malignanciesZIABC011823 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI SHAH, NIRALI · 2019 to 2025
$6.1M
CCR NIH HHS ZIA BC 011823Gateway FoundationIntramural NIH HHS ZIC SC006537
6 · The paper itself

Abstract

introductionVincristine sulfate liposome injection (VSLI), a liposomal formulation of vincristine, may be better tolerated than standard aqueous vincristine and enable dose intensification. PROCEDURES: Based on single-agent tolerability, activity, and FDA approval in adults with acute lymphoblastic leukemia (ALL), we tested the safety and feasibility of VSLI as replacement for standard vincristine in the UK ALL R3 mitoxantrone-based four-drug induction (Cohort A), a three-drug anthracycline-free induction (Cohort B), and maintenance chemotherapy (Cohort C) in children and young adults with relapsed/refractory B-cell ALL.

resultsAmong 29 participants with a median age of 12.4 years (range: 1.8-19.6 years), 16 received Cohort A, eight received Cohort B, and five received Cohort C therapy. Dose level 1 (DL1): 1.5 mg/m

conclusionBased on the promising response signal in this heavily pretreated population, further study of VSLI is warranted. (ClinicalTrials.gov NCT02879643).

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsNeoplasm Recurrence, LocalPrecursor Cell Lymphoblastic Leukemia-LymphomaVincristineAdolescentAdultChildChild, PreschoolFemaleFollow-Up StudiesHumansInfantLiposomesMalePrognosisYoung AdultLiposomesVincristineacute lymphoblastic leukemiacombination chemotherapyrelapsevincristine

Identifiers

PMID39937083
PMCPMC12278299

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.